ClinicalTrials.gov
public full text
Public Domain
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety Study of Pritumumab in Brain Cancer#883476
- Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors#1100516
- The current role of surgery for single brain metastases / Tunc Faik Ersoy, Daniel Brainman, Diyan Dimov, Roland Coras, Björn Berger, Florian Weissinger, Matthias Simon#1078597
- Pembro+Chemo in Brain Mets#1046180
- Toronto BNB Pilot Study#869532
Record · ID 980390
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive